Novartis
NEWS
Ziextenzo (pegfilgrastim) is a long-acting version of filgrastim and is indicated to decrease the incidence of infection in cancer patients.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
Novartis said it will work diligently with the FDA to resolve the partial clinical hold and resume the study.
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
The agreement revolves around the development and commercialization of Pliant’s preclinical candidate, PLN-1474, and up to three more integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
Last week was busy for clinical trial news. Here’s a look.
JOBS
IN THE PRESS